Medicine Prices

Philips cuts annual sales outlook as China demand deteriorates further

Adjusted earnings before interest, taxes and amortisation (EBITA) were exactly in line with expectations at 516 million euros, up 13 per cent year-on-year, as lower costs pushed the profit margin up

Olympus CEO resigns after allegations of illegal drug purchase, shares fall

Olympus' 6 per cent tumble put the company's shares on track for their biggest one-day fall in nearly three months

Cost a key factor for US Medicaid coverage of weight-loss drugs: Report

Half of the states without coverage said they are considering adding them or evaluating their coverage, it said

NPPA raises ceiling prices of 8 scheduled drugs for asthma, TB, glaucoma

Ceiling prices were also revised for the asthma drug Salbutamol in tablets of 2 mg and 4 mg formulations and respirator solution of 5 mg/ml formulation

CDSCO flags substandard batches in over 50 commonly prescribed drugs

More than 50 widely prescribed medications, including treatments for high blood pressure, acid reflux, and erectile dysfunction, were identified as substandard in quality

Orchid AMS eyes Rs 300 cr turnover in 3 years for antimicrobial resistance

Orchid Pharma's newly-formed antimicrobial solutions division is targeting a turnover of up to Rs 300 crore in the next three years with about 250 strong salespeople onboard while combating the challenge of antimicrobial resistance in India, according to a top company official. Orchid AMS (Antimicrobial Solutions) is targeting to partner with around 2,500-3,000 hospitals and healthcare institutions in the next two to three years to implement effective antimicrobial stewardship programmes (AMSPs). Antimicrobial resistance is one of the biggest healthcare challenges beyond the hospitals as medications are available easily without prescriptions and antibiotics are also coming in through poultry, fish and through crops, Rajnish Rohatgi, CEO, Orchid AMS, a division of Orchid Pharma, told PTI. "This is a humongous issue. We felt that not only from a business aspect of creating a difference but it provides us a motivating purpose beyond business and to give back to society in our own way,

Aesthetic medicine mkt to triple by 2029, driven by non-surgical procedures

India's current aesthetic medicine market stands at approximately $1.62 billion and is expected to grow at a compound annual growth rate (CAGR) of 13.2 per cent

HIV medicine that costs $42,000 could be made for just $40 with profits

Lenacapavir drug hailed as 'the closest we have ever been to an HIV vaccine', is currently sold by US pharma major Gilead at Rs $42,250 for the first year

Govt expands committee for drugs, medical devices pricing reforms

According to an industry source, the committee will also look at ways to design a price moderation framework for medical devices while providing incentives to the medtech industry to minimize imports

Prices of essential medicines will not be increased in FY25: Mandaviya

Union Minister Mansukh Mandaviya said on Thursday said there will be no increase in prices of essential medicines this fiscal year in view of negligible growth in wholesale price-based inflation. In an interaction with PTI editors at the news agency's headquarters here, Mandaviya -- the Union Chemicals and Fertilisers Minister -- assured that this is "Modiji's guarantee". When asked about reports and speculations of hike in rates of essential drugs, he said, "It is absolutely incorrect. There will be no increase in the price of medicines". The minister said the National Pharmaceutical Pricing Authority (NPPA), which is under the Department of Pharmaceuticals, annually revises the ceiling prices of scheduled medicines on the basis of Wholesale Price Index (WPI). "NPPA monitors and fixes the prices of essential medicines based on WPI," Mandaviya said. When inflation rises, it leads to a hike in prices and when it goes down, the prices come down, the minister said. "This year the ..

Essential drug prices stay flat this year, offering relief to consumers

This would come after the price hikes allowed (in line with the change in WPI) in the previous two years were 12.12 per cent (2023) and 10.7 per cent (2022) respectively

Central homoeopathy body notifies new rules for assessment of BHMS colleges

According to the NCH notification, each existing institution will now have to submit information and relevant annexures needed for the assessment and rating on an annual basis

Pharma regulation: A complex problem

Medicines are critical for human wellbeing but its regulation, which is inherently complex, is even more challenging in India

Pharmeasy FY23 losses widen 31%, revenue increases 16% to Rs 6,644 cr

Online pharmacy dropped plan for an IPO in 2022, says it is cutting down expenses

Govt orders CBI probe into substandard medicine supply in Delhi hospitals

Test reports for eleven medicinal samples are still pending with the government labs

General medicine most consulted speciality under PMJAY: NHA data

NHA has described PMJAY's primary objectives as ensuring comprehensive coverage for catastrophic illnesses, reducing out-of-pocket expenditure, and improving access to hospitalisation care

2023 Nobel Prize in medicine goes to Katalin Karikó, Drew Weissman

The 2023 Nobel Prize in Physiology or Medicine has been awarded to Drew Weissman and Katalin Karikó for their contributions to the development of the highly effective mRNA vaccines against Covid-19

Indian pharma Industry to log 8-10% revenue growth in FY24: Report

Drugs in the National List of Essential Medicines contribute 17% of revenue: ICRA

Merck sues federal govt over plan to negotiate Medicare drug prices

Merck is suing the federal government over a plan to negotiate Medicare drug prices, calling the programme a sham equivalent to extortion. The drugmaker is seeking to halt the programme, which was laid out in the Inflation Reduction Act and is expected to save taxpayers billions of dollars in the coming years. Merck said in a complaint filed Tuesday that the programme does not involve genuine negotiation. Instead, it said the U.S. Department of Health and Human Services selects drugs to be included and then dictates the price, threatening drugmakers with a ruinous daily excise tax if they decline to agree. It is tantamount to extortion, the drugmaker said in the complaint, which was filed in the U.S. District Court for the District of Columbia. The drugmaker added that it expects its diabetes treatment Januvia to be part of the IRA's scheme starting later this year. Representatives of the federal agency did not immediately respond to requests for comment from The Associated Press

NPPA allows drug firms to raise prices of essential medicines from April 1

Effectively the prices of 651 medicines will come down by 6.73%; WPI-linked price rise allowed this fiscal is 12.2%; about 870 formulations fall under the essential category